Bad Blood: Secrets and Lies in a Silicon Valley Startup
John Carreyrou
2018-05 · Penguin Random House Audio · Skaito Will Damron
4,7star
76 apžvalgos
headphones
Garsinė knyga
11 val. 36 min.
Nesutrumpinta
family_home
Tinkama
info
Norite nemokamo 10 min. trukmės pavyzdžio? Klausykite bet kada, net neprisijungę.
Pridėti
Apie šią garsinę knygą
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
Įvertinimai ir apžvalgos
4,7
76 apžvalgos
Apie autorių
JOHN CARREYROU is a two-time Pulitzer-prize winning investigative reporter at The Wall Street Journal. For his extensive coverage of Theranos, Inc., Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism and the Barlett & Steele Award for Investigative Journalism in 2016. Carreyrou lives in Brooklyn with his wife and three children.
Įvertinti šią garsinę knygą
Pasidalykite savo nuomone.
Klausymo informacija
Išmanieji telefonai ir planšetiniai kompiuteriai
Įdiekite „Google Play“ knygų programą, skirtą „Android“ ir „iPad“ / „iPhone“. Ji automatiškai susinchronizuojama su paskyra ir jūs galite skaityti tiek prisijungę, tiek neprisijungę, kad ir kur būtumėte.
Nešiojamieji ir staliniai kompiuteriai
Galite skaityti knygas, kurias įsigyjate „Google Play“, naudodami kompiuterio žiniatinklio naršyklę.
